Aclaris Therapeutics
ACRS
96 hedge funds and large institutions have $586M invested in Aclaris Therapeutics in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 15 closing their positions.
116% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $675K
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
9% more capital invested
Capital invested by funds: $536M → $586M (+$50.4M)
1.35% more ownership
Funds ownership: 98.94% → 100.29% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 100 → 96 (-4)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$7.3M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$6.02M |
| 4 |
BlackRock
New York
|
+$3.77M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$3.47M |
Top Sellers
ACRS Hedge Fund Activity: Q2 2018 in Review
96 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2018, worth a combined $586M — up 9.4% from $536M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ACRS and 12 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 40 added.
The largest buyer was Fidelity Investments, adding an estimated $14.7M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $9.24M sold.
- 96 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2018, down from 100 in Q1 2018.
- Funds reported $586M of Aclaris Therapeutics stock for Q2 2018, up 9.4% quarter-over-quarter.
- 12 funds opened new Aclaris Therapeutics positions in Q2 2018 and 15 closed out, a net change of -3 holders.
- The largest Aclaris Therapeutics buyer in Q2 2018 was Fidelity Investments, an estimated $14.7M added.
- The largest Aclaris Therapeutics seller in Q2 2018 was Loomis, Sayles & Company, an estimated $9.24M sold.
Based on aggregated 13F filings for Q2 2018.